{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.005","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.3","upperLimit":"55.1","value":"49.7"},{"groupId":"OG001","lowerLimit":"29.6","upperLimit":"44.3","value":"37"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"328"},{"groupId":"OG001","value":"165"}],"units":"Participants"}],"description":"ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"150 mg Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG000","title":"Abemaciclib + NSAI"},{"description":"Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).","id":"OG001","title":"Placebo + NSAI"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Randomization to Progressive Disease or Death Due to Any Cause (Up to 32 Months)","title":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}